On 19 November, Hemotune has won the Swiss Technology Award 2020 in the “Start up” category. It received the award for its medical blood purification device that enables therapeutic blood purification with much greater efficiency and precision compared to existing methods.
The prize, which is awarded by the Swiss Economic Forum, aims to promote a culture of innovation within Switzerland and serves as recognition for exceptional companies in the three categories of Innovation Leaders, Start-ups and Inventors. The key criterion for the selection is a groundbreaking technology, but progress in implementation, social and ecological impact and economic prospects also play a role.
Hemotune develops the HemoSystem, a revolutionary medical device for blood purification that combines cutting-edge scientific results from biomedicine and nanotechnology. The primary applications of the technology are sepsis and septic shock, as a result of which, according to the WHO, up to 6 million people die each year. Since blood poisoning is also one of the complications that can occur as a result of an infection with the coronavirus, HemoSystem could therefore also play an important role in the corona pandemic.
This is the reason why EIT Health decided to co-invest EUR 500,000 in Hemotune in July 2020, through the Startup Rescue Instrument. Hemotune was 1 of 11 European start-ups that were selected to receive the highly coveted EIT Health funding, as part of the EIT Crisis Response Initiative. The co-investment was intended to speed up our development activities in order to bring Hemotune’s live-saving sepsis therapy to the clinics as soon as possible.
If you want to know more Hemotune, check out their video or read our interview with the team.